TOP > 外国特許検索 > PHARMACEUTICAL COMPOSITION

PHARMACEUTICAL COMPOSITION

外国特許コード F180009326
整理番号 (AF13P005)
掲載日 2018年1月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP023162
国際公開番号 WO 2017222040
国際出願日 平成29年6月23日(2017.6.23)
国際公開日 平成29年12月28日(2017.12.28)
優先権データ
  • 特願2016-124992 (2016.6.23) JP
発明の名称 (英語) PHARMACEUTICAL COMPOSITION
発明の概要(英語) The present invention provides a pharmaceutical composition which can be administered to a human body safely and is effective for the treatment of PolyQ diseases. The present invention provides: a pharmaceutical composition which contains arginine, a physiologically acceptable salt of arginine or a solvate of arginine or the physiologically acceptable salt as an active ingredient and can be used for the treatment or prevention of a PolyQ disease; and the pharmaceutical composition described above, wherein the PolyQ disease is Huntington's disease, hereditary spinocerebellar ataxia, dentatorubropallidoluysial atrophy or spinal and bulbar muscular atrophy.
従来技術、競合技術の概要(英語) BACKGROUND ART
In accordance with the aging population, age-related neurodegenerative diseases andcorticosteroids continues to increase and, because there is no effective treatment has been a serious social problem. Therefore, these effective for the neurodegenerative disease is demanded development of a drug.
Age-related neurodegenerative diseases andcorticosteroids PolyQ to one of the diseases. PolyQ diseases include, Huntington's Disease, spinocerebellar ataxia and the like of the various, cause abnormal extension of the chain in the protein (40 amino acids>) PolyQ by hereditary neurodegenerative disorders 9 to develop one generic. Is about 7000-8000 of a person suffering from Japan and the user is estimated, is not yet effective methods for treating intractable. PolyQ individuals, an abnormality cause by extension of PolyQ misfolded protein chain, resulting in the aggregation, as a result are considered to cause neurodegeneration.
Chemical chaperones, to stabilize the native conformation of the protein, protein folding rate of the reaction or affect the fidelity by, an anti-agglomeration properties are exhibited. Arginine, and expressed in E. coli protein aggregation of various recombinant and in order to increase the solubility, the most commonly used one of the additive (non-patent document 1). From the effects of anti-coagulant this nonspecific, arginine, such as Parkinson's disease and Alzheimer's disease by misfolding of a protein to be effective in the treatment. In fact, arginine, amyloid β peptide (1-42) is to prevent aggregation of the reported (Non-Patent Document 2).
Arginine, including a human organism species of amino acids constituting the 1, can be safely administered to an animal such as a human can. Arginine is, other than disease PolyQ disease in a clinical trial, safety is established (non-patent document 3, 4). Also, arginine, the blood-brain barrier (BBB) to pass through known (Non-Patent Document 5).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • NAGAI Yoshitaka
  • POPIEL Helena Akiko
  • MINAKAWA Eiko
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
参考情報 (研究プロジェクト等) CREST Creation of a Novel Technology towards Diagnosis and Treatment based on Understanding of Molecular Pathogenesis of Psychiatric and Neurological Disorders AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close